C17 Council Report issue

Foundation Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2010
NCT01135550
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

C17 Council (regulatory sponsor)

Active Ingredients

Drugs in Phase 3 Trials (1)

urea (1 trial)

Drugs in Phase 2 Trials (2)

pazopanib (votrient) (1 trial)

topotecan (hycamtin) (1 trial)

Drugs in Phase 1 Trials (1)

melatonin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Headache (Phase 3)

Neoplasms (Phase 2)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4